Clay B. Siegall, President and CEO at Immunome Inc. (IMNM), bought 25,450 shares at $19.67 ($501K) on 2026-03-27, disclosed to the SEC on 2026-03-31.
CEO Clay B. Siegall purchased 25,450 shares for $500,601, signaling confidence in the company's pipeline. This buyback occurs as the stock has surged 224.96% over the past year, though it remains 20.9% below its 52-week high of $27.65.
IMNM is up 8.21% over the last five days and 224.96% over the last year, trading 20.9% below its 52-week high of $27.65.
Catalysts include the FDA NDA submission for varegacestat filed on May 12 and an oral presentation at the 2026 ASCO Annual Meeting on May 11.
The stock carries high volatility with a beta of 2.115 and faces significant short interest at 19.27% of the float.
Nothing distinguishes this filing.
| Filing → |
| IMNM | BUY | 2025-12-22 | $298K | — | Filing → |
| IMNM | BUY | 2025-12-18 | $2.0M | — | Filing → |
| IMNM | BUY | 2025-03-26 | $999K | — | Filing → |